Journal of Digestive Cancer Research

  • 제4권2호
  • /
  • Pages.92-98
  • /
  • 2016
  • /
  • 2950-9394(pISSN)
  • /
  • 2950-9505(eISSN)
대한소화기암연구학회 (Korean Society of Gastrointestinal Cancer Research)
권호 표지

Liver Resection for Hepatocellular Carcinoma Beyond BCLC A Stage

  • Tianqiang Song (Department of HepatoBiliary Tumor, Tianjin Medical University Cancer Institute And Hospital) ;
  • Ti Zhang (Department of HepatoBiliary Tumor, Tianjin Medical University Cancer Institute And Hospital) ;
  • Wei Zhang (Department of HepatoBiliary Tumor, Tianjin Medical University Cancer Institute And Hospital) ;
  • Feng Fang (Department of HepatoBiliary Tumor, Tianjin Medical University Cancer Institute And Hospital) ;
  • Qiang Wu (Department of HepatoBiliary Tumor, Tianjin Medical University Cancer Institute And Hospital) ;
  • Yunlong Cui (Department of HepatoBiliary Tumor, Tianjin Medical University Cancer Institute And Hospital) ;
  • Huikai Li (Department of HepatoBiliary Tumor, Tianjin Medical University Cancer Institute And Hospital) ;
  • Qiang Li (Department of HepatoBiliary Tumor, Tianjin Medical University Cancer Institute And Hospital)
  • 투고 : 2016.11.30
  • 심사 : 2016.12.21
  • 발행 : 2016.12.31
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

The barcelona clinic liver cancer (BCLC) staging systemis regarded as the optimal staging system to predict prognosis and guide treatmentfor hepatocellular carcinoma (HCC) .According to the BCLC classification, only patients with BCLC A stage should undergo liver resection. In contrast, patients with intermediate-advanced HCC should be scheduled for palliative therapies,such as transcatheter arterial chemoembolization (TACE) and target therapy, even if the lesion is resectable. More and more studies report good short-term and long-term outcomes in patients with intermediate-advanced HCC treated by radical resection and many patients benefited from curative resection. The aim of this review was to evaluate the role of surgery beyond the BCLC recommendations. A revision of the BCLC algorithm should be proposed.

키워드

참고문헌

  1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
  2. Venook AP, Papandreou C, Furuse J, de Guevara LL. The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective. Oncologist 2010;15 Suppl 4:5-13.
  3. Yi PS, Zhang M, Zhao JT, Xu MQ. Liver resection for intermediate hepatocellular carcinoma. World J Hepatol 2016;8(14):607-615.
  4. Guglielmi A, Ruzzenente A, Conci S, Valdegamberi A, Vitali M, Bertuzzo F, De Angelis M, Mantovani G, Iacono C. Hepatocellular carcinoma: Surgical perspectives beyond the barcelona clinic liver cancer recommendations. World J Gastroenterol 2014;20(24):7525-7533.
  5. Schmidt S, Follmann M, Malek N, Manns MP, Greten TF. Critical appraisal of clinical practice guidelines for diagnosis and treatment of hepatocellular carcinoma. J Gastroenterol Hepatol 2011;26:1779-1786.
  6. Maida M, Orlando E, Camma C, Cabibbo G. Staging systems of hepatocellular carcinoma: a review of literature. World J Gastroenterol 2014;20:4141-4150 .
  7. Vauthey JN, Lauwers GY, Esnaola NF, et al. Simplified staging for hepatocellular carcinoma. J Clin Oncol 2002;20(6):1527-1536.
  8. Forner A, Reig ME, de Lope CR, Bruix J. Current strategy for staging and treatment: the BCLC update and future prospects. Semin. Liver Dis 2010;30:61-74.
  9. Fong ZV, Tanabe KK. The clinical management of hepatocellular carcinoma in the United States, Europe, and Asia: a comprehensive and evidence-based comparison and review. Cancer 2014;120:2824-2838.
  10. Cabibbo G, Enea M, Attanasio M, Bruix J, Craxi A, Camma C. A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma. Hepatology 2010;51:1274-1283.
  11. Cillo U, Bassanello M, Vitale A, et al. The critical issue of hepatocellular carcinoma prognostic classification: which is the best tool available? J. Hepatol 2004;40:124-131.
  12. Marrero JA, Fontana RJ, Barrat A, Askari F, Conjeevaram HS, Su GL, Lok AS. Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort. Hepatology 2005;41:707-716.
  13. Llovet, J. M., Bru, C. &Bruix, J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis. 1999;19:329-338.
  14. Llovet JM, Real MI, Montana X, et al. Barcelona Liver Cancer Group.Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002;359:1734-1739.
  15. Llovet JM, Ricci S, Mazzaferro V, et al. SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-390.
  16. Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo- controlled trial. Lancet Oncol 2009;10:25-34.
  17. Ferenci P, Fried M, Labrecque D, et al. World Gastroenterology Organization. Hepatocellularcarcinoma (HCC): a global perspective. J Clin Gastroenterol 2010;44:239-245.
  18. Verslype C, Rosmorduc O, Rougier P. Hepatocellular carcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012;23Suppl 7:41-48.
  19. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011;53:1020-1022.
  20. European Association for the Study of the Liver; European Organization for Research and Treatment of Cancer. EASLEORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012;56:908-943.
  21. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003;37:429-442.
  22. Wang JH, Changchien CS, Hu TH, et al. The efficacy of treatmentschedules according to Barcelona Clinic Liver Cancer staging forhepatocellular carcinoma - Survival analysis of 3,892 patients. EurJ Cancer 2008;44:1000-1006.
  23. Ho MC, Huang GT, Tsang YM, et al. Liver resection improves the survival of patients with multiplehepatocellular carcinomas. Ann Surg Oncol 2009;16:848-855.
  24. Lin CT, Hsu KF, Chen TW, et al. Comparing hepaticresection and transarterial chemoembolization for Barcelona Clinic Liver Cancer (BCLC) stage B hepatocellular carcinoma: changefor treatment of choice? World J Surg 2010;34:2155-2161.
  25. Hsu CY, Hsia CY, Huang YH, et al. Comparisonof surgicalresection and transarterial chemoembolization forhepatocel lular carcinoma beyond the Milan criteria: a propensityscore analysis. Ann Surg Oncol 2012;19:842-849.
  26. Zhong JH, Ke Y, Gong WF, et al. Hepatic resection associated with good survivalfor selected patients with intermediate and advanced-stagehepatocellular carcinoma. Ann Surg 2014;260:329-340.
  27. Zhong JH, Xiang BD, Gong WF, et al. Comparison of long-term survival of patients with BCLC stage B hepatocellular carcinoma after liver resection or transarterialchemoembolization. PLoS One 2013;8:e68193.
  28. Torzilli G, Belghiti J, Kokudo N, et al. A snapshot of the effective indicationsand results of surgery for hepatocellular carcinomain tertiary referral centers: is it adherent to the EASL/AASLD recommendations?: an observational study of the HCCEast-West study group. Ann Surg 2013;257:929-937.
  29. Yin L, Li H, Li AJ, Lau WY, Pan ZY, Lai EC, Wu MC, Zhou WP. Partial hepatectomy vs. transcatheter arterial chemoem-bolizationfor resectable multiple hepatocellular carcinoma beyond Milan Criteria: a RCT. J Hepatol 2014;61:82-88.
  30. Roayaie S, Jibara G, Tabrizian P, et al. The Role of hepatic resection in the treatment of hepatocellular cancer. Hepatology 2015;62:440-451.
  31. Vitale A, Burra P, Frigo AC, et al. Italian Liver Cancer (ITA. LI. CA) group. Survival benefit of liver resection for patients with hepatocellular carcinoma across different Barcelona Clinic Liver Cancer stages: A multicentre study. J Hepatol 2015;62:617-624.
  32. Farinati F, Vanin V, Giacomin A, et al. BCLC stage B hepatocellular carcinoma and transcatheter arterial chemoembolization: a 20-year survey by the Italian Liver Cancer group. Liver Int 2015;35:223-231.
  33. Qi X, Wang D, Su C, Li H, GuoX. Hepatic resection versus transarterial chemoembolization for the initial treatment ofhepatocellular carcinoma: A systematicreview and meta-analysis. Oncotarget 2015;6(21):18715-18733.
  34. Mazzaferro V, Roayaie S, Poon R, Majno PE. Dissecting EASL/AASLD Recommendations With a More Careful Knife: A Comment on "Surgical Misinterpretation" of the BCLC Staging System. Ann Surg 2015;262(1):e17-18.
  35. Burrel M, Reig M, Forner A, et al. Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) usingDrug Eluting Beads. Implications for clinical practice and trial design. J Hepatol 2012;56(6):1330-1335.
  36. Llovet JM, Bustamante J, Castells A, et al. Natural history of untreatednonsurgical hepatocellular carcinoma: rationale for the designand evaluation of therapeutic trials. Hepatology 1999;29:62-67.
  37. Wang Y, Yuan L, Ge RL, Sun Y, Wei G. Survival benefit ofsurgical treatment for hepatocellular carcinoma with inferiorvena cava/right atrium tumor thrombus: results of aretrospective cohort study. Ann Surg Oncol 2013;20:914-922.
  38. Predictive factors for long term prognosis after partial hepatectomyfor patients with hepatocellular carcinoma in Japan. The Liver Cancer Study Group of Japan. Cancer 1994;74:2772-2780
  39. Kanda M, Tateishi R, Yoshida H, et al. Extrahepatic metastasis of hepatocellular carcinoma: incidence and risk factors. Liver Int 2008;28:1256-1263.
  40. Pawlik TM, Poon RT, Abdalla EK, et al. Hepatectomy for hepatocellularcarcinoma with major portal or hepatic vein invasion: resultsof a multicenter study. Surgery 2005;137:403-410.
  41. Le Treut YP, Hardwigsen J, Ananian P, et al. Resection of hepatocellular carcinomawith tumor thrombus in the major vasculature. A Europeancase-control series. J Gastrointest Surg 2006;10:855-862.
  42. Ruzzenente A, Capra F, Pachera S, et al. Is liver resection justified in advanced hepatocellular carcinoma? Results of an observational study in 464 patients. J Gastrointest Surg 2009;13:1313-1320.
  43. Inoue Y, Hasegawa K, Ishizawa T, et al. Is thereany difference in survival according to the portal tumorthrombectomy method in patients with hepatocellular carcinoma? Surgery 2009;145:9-19 .
  44. Ban D, Shimada K, Yamamoto Y, Nara S, Esaki M, Sakamoto Y, Kosuge T. Efficacy of a hepatectomy and a tumor thrombectomyfor hepatocellular carcinoma with tumor thrombusextending to the main portal vein. J Gastrointest Surg 2009;13:1921-1928.
  45. Chok KS, Cheung TT, Chan SC, Poon RT, Fan ST, Lo CM. Surgical outcomes in hepatocellular carcinoma patients with-portal vein tumor thrombosis. World J Surg 2014;38:490-496.
  46. Wang Y, Yuan L, Ge RL, Sun Y, Wei G. Survival benefit of surgical treatment for hepatocellular carcinoma with inferiorvena cava/right atrium tumor thrombus: results of aretrospective cohort study. Ann Surg Oncol 2013;20:914-922.
  47. Kokudo T, Hasegawa K, Matsuyama Y, et al. Liver Cancer Study Group of Japan. Survival benefit of liver resection for-hepatocellular carcinoma associated with portal vein invasion. J Hepatol 2016;65(5):938-943.
  48. Torzilli G, Belghiti J, Kokudo N, et al. A snapshot of the effective indications andresults of surgery for hepatocellular carcinoma in tertiary referral centers: is it adherentto the EASL/AASLD recommendations?: an observational study of the HCC East-West study group. Ann Surg 2013;257(5):929-937.
  49. Chok KS, Cheung TT, Chan SC, Poon RT, Fan ST, Lo CM. Surgical outcomes in hepatocellular carcinoma patients with-portal vein tumor thrombosis. World J Surg 2014;38:490-496.
  50. Wu CC, Hsieh SR, Chen JT, et al. An appraisal of liver and portal vein resectionfor hepatocellular carcinoma with tumor thrombi extendingto portal bifurcation. Arch Surg 2000;135:1273-1279.
  51. Inoue Y, Hasegawa K, Ishizawa T, et al. Is thereany difference in survival according to the portal tumorthrombectomy method in patients with hepatocellular carcinoma? Surgery 2009;145:9-19.
  52. Ban D, Shimada K, Yamamoto Y, et al. Efficacy of a hepatectomy and a tumor thrombectomy for hepatocellular carcinoma with tumor thrombusextending to the main portal vein. J Gastrointest Surg 2009;13:1921-1928.
  53. Zhong JH, Rodriguez AC, Ke Y, Wang YY, Wang L, Li LQ. Hepatic resection as a safe and effective treatment for heaptocellularcar cinoma involving a single largetumor, multiple tumors, or macrovascular invasion. Medicine(Baltimore). 2015;94(3):e396.
  54. Lencioni R. Chemoembolization in patients with hepatocellular carcinoma. Liver Cancer 2012;1(1):41-50.
  55. Kudo M. Treatment of advanced hepatocellular carcinoma with emphasis on hepatic arterial infusion chemotherapy and molecular targeted therapy. Liver Cancer 2012;1:62-70.
  56. Jihye C, Jinsil S. Application of radiotherapeutic strategies in the BCLC-defined stages of hepatocellular carcinoma. Liver Cancer 2012;1:216-225.
  57. Hsu HC, Chen TY, Chiu KW, et al. Three-dimensional conformal radiotherapy for the treatment of arteriovenous shunting in patients with hepatocellular carcinoma. Br J Radiol 2007;80:38-42.
  58. Lau WY, Lai EC: Salvage surgery following downstaging of unresectable hepatocellular carcinoma - a strategy to increase resectability. Ann Surg Oncol 2007;14:3301-3309.
  59. Han KH, Seong J, Kim JK, Ahn SH, Lee Y, Chon CY. Pilot clinical trial of localized concurrent chemora- diation therapy for locally advanced hepatocellular carcinoma with portal vein thrombosis. Cancer 2008;113:995-1003.
  60. Meng MB, Cui YL, Lu Y, et al. Transcatheter arterial chemoembolization in combination with radiotherapy for unresectable hepatocellular carcinoma: A systematic review and meta-analysis. Radiother Oncol 2009;92:184-194.
  61. Seong J. Challenge and hope in radiotherapy of hepatocellular carcinoma. Yonsei Med J 2009;50:601-612.
  62. Choi SB, Kim KS, Park YN, et al. The efficacy of hepatic resection after neoadjuvant transarterial chemoembolization (TACE) and radiation therapy in hepatocellular carcinoma greater than 5 cm in size. J Korean Med Sci 2009;24:242-247.
  63. Yu W, Gu K, Yu Z, et al. Sorafenib potentiates irradiation effect in hepatocellular carcinoma in vitro and in vivo. Cancer Lett 2013;329:109-117.
  64. Lee S, Kim BK, Kim SU, et al. Efficacy of sorafenib monotherapy versus sorafenib-based loco-regional treatments in advanced hepatocellular carcinoma. PLoS ONE 2013;8:e77240.
  65. Liapi E, Geschwind JF. Combination of local transcatheter arterial chemoembolization and systemic anti-angiogenic therapy for unresectable hepatocellular carcinoma. Liver Cancer 2012;1(3-4):201-215.
  66. Bolondi L, Burroughs A, Dufour JF, et al. Heterogeneity of patients with intermediate (BCLC B) hepatocellular carcinoma: proposal for a subclassification to facilitate treatment decisions. Semin Liver Dis 2012;32:348-359.
  67. Kudo M1, Arizumi T, Ueshima K, Sakurai T, Kitano M, Nishida N. Subclassification of BCLC B stage hepatocellular carcinoma and treatment strategies: Proposal of Modified Bolondi's Subclassification (Kinki Criteria). Dig Dis 2015;33(6):751-758.
  68. Sinn DH, Cho JY, Gwak GY, et al. Different survival of Barcelona clinic liver cancer stage C hepatocellular carcinoma patients by the extent of portal vein invasion and the type of extrahepatic spread. PLoS One 2015;10(4):e0124434.